| Plasma free triiodothyronine response to thyrotropin-releasing hormone to predict the remission of Graves' disease treated with antithyroid drugs. | |
| | |
MedLine Citation:
|
PMID: 1713218 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The responses of both plasma TSH and free T3 (FT3) to TRH were examined in 31 patients with Graves' disease who were euthyroid after treatment with antithyroid drugs, 6 patients with primary hypothyroidism, and 14 control subjects. TSH was measured 0, 15, 30, 60, 90, and 120 min and FT3 was measured 0, 30, 60, 90, 120, 150, and 180 min after TRH injection (500 microgram, iv). The increment in FT3 above the basal level (delta FT3) in normal controls ranged from 1.2-3.7 pmol/L, with a mean +/- SD of 2.2 +/- 0.8 pmol/L. The mean (+/- SD) delta FT3 in patients with primary hypothyroidism was 0.3 +/- 0.2 pmol/L. After the TRH test, antithyroid drugs were stopped in patients with Graves' disease. Nine of 31 Graves' patients relapsed within 6 months after the TRH test. The other 22 patients with Graves' disease were followed while in remission during the observation period of up to 48 months. The mean (+/- SD) delta FT3 were significantly lower in 9 Graves' patients who relapsed than in those who achieved remission (0.5 +/- 0.3 vs. 2.6 +/- 1.1 pmol/L; P less than 0.01). Eight of 9 Graves' patients who relapsed showed lower delta FT3 values than the lowest value (1.1 pmol/L) in 22 Graves' patients in remission. Although the mean increment of TSH above the basal level (delta TSH) was also significantly different between the Graves' patients who relapsed and those in remission (1.4 vs. 12.3 mU/L; P less than 0.01), there was considerable overlap between the 2 groups. These findings suggest that delta FT3 reflects the endocrinological recovery of the pituitary-thyroid axis and is a beneficial indicator for the termination of antithyroid drugs in Graves' disease. |
| | |
Authors:
|
K Notsu; N Oka; Y Masaki; H Furuya; Y Kato |
Related Documents
:
|
19226198 - Clinical evolution of autoimmune thyroiditis in children and adolescents. 9282558 - Heart in hypothyroidism--an echocardiographic study. 6627698 - Natural history of thyroid function in diabetics with impaired thyroid reserve: a four ... 3921948 - Confusion and paranoia associated with oral tocainide. 10471618 - Noninvasive diagnosis of emphysema. aerosol morphometry and aerosol bolus dispersion in... 2951138 - Autonomic neuropathy and diabetic foot ulceration. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 73 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 1991 Aug |
Date Detail:
|
Created Date: 1991-08-27 Completed Date: 1991-08-27 Revised Date: 2005-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 396-400 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Shimane Medical University, Izumo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antithyroid Agents
/
therapeutic use* Female Graves Disease / blood, drug therapy* Humans Hypothyroidism / blood, drug therapy* Male Prognosis Reference Values Thyrotropin-Releasing Hormone / diagnostic use* Time Factors Triiodothyronine / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Antithyroid Agents; 24305-27-9/Thyrotropin-Releasing Hormone; 6893-02-3/Triiodothyronine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Parotid salivary secretion in diabetic autonomic neuropathy.
Next Document: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of p...